Items where authors include "Redini, F."
Up a levelArticle
Crenn, V., Biteau, K., Amiaud, J. et al. (8 more authors) (2017) Bone microenvironment has an influence on the histological response of osteosarcoma to chemotherapy : retrospective analysis and preclinical modeling. American Journal of Cancer Research, 7 (11). pp. 2333-2349.
Cordova, L.A., Guilbaud, F., Amiaud, J. et al. (6 more authors) (2016) Severe Compromise of Preosteoblasts in a Surgical Mouse Model of Bisphosphonate-Associated Osteonecrosis of the Jaw. Journal of Craniomaxillofacial Surgery, 44 (9). pp. 1387-1394. ISSN 1010-5182
Guiho, R., Biteau, K., Grisendi, G. et al. (6 more authors) (2016) TRAIL Delivered by Mesenchymal Stromal/Stem Cells Counteracts Tumor Development in Orthotopic Ewing Sarcoma Models. International Journal of Cancer. ISSN 0020-7136
Ory, B., Baud'huin, M.E., Verrecchia, F. et al. (7 more authors) (2016) Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma Progression. Clinical Cancer Research, 22 (10). pp. 2520-2533. ISSN 1078-0432
Biteau, K., Guiho, R., Chatelais, M. et al. (5 more authors) (2016) L-MTP-PE and zoledronic acid combination in osteosarcoma: pre-clinical evidence of positive therapeutic combination for clinical transfer. American Journal of Cancer Research, 6 (3). 0025208. pp. 677-689. ISSN 2156-6976
Redini, F. and Heymann, D. orcid.org/0000-0001-7777-0669 (2015) Bone Tumor Environment as a Potential Therapeutic Target in Ewing Sarcoma. Frontiers in Oncology, 5. 279. pp. 1-11. ISSN 2234-943X
Lamora, A., Mullard, M., Amiaud, J. et al. (4 more authors) (2015) Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases. Oncotarget, 6 (16). pp. 14413-14427. ISSN 1949-2553
Lezot, F., Chesneau, J., Navet, B. et al. (9 more authors) (2015) Skeletal consequences of RANKL-blocking antibody (IK22-5) injections during growth: Mouse strain disparities and synergic effect with zoledronic acid. BONE, 73. pp. 51-59. ISSN 8756-3282
Guihard, P., Boutet, M-A., Royer, BB-L. et al. (8 more authors) (2015) Oncostatin M, an Inflammatory Cytokine Produced by Macrophages, Supports Intramembranous Bone Healing in a Mouse Model of Tibia Injury. American Journal of Pathology, 185 (3). pp. 765-775. ISSN 0002-9440
Gobin, B., Baud'Huin, M., Lamoureux, F. et al. (8 more authors) (2015) BYL719, a new alpha-specific PI3K inhibitor: Single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma. International Journal of Cancer, 136 (4). pp. 784-796. ISSN 0020-7136
Guiho, R., Biteau, K., Heymann, D. orcid.org/0000-0001-7777-0669 et al. (1 more author) (2015) TRAIL-based therapy in pediatric bone tumors: how to overcome resistance. Future Oncology, 11 (3). pp. 535-542. ISSN 1479-6694
Lezot, F., Chesneau, J., Battaglia, S. et al. (5 more authors) (2014) Preclinical evidence of potential craniofacial adverse effect of zoledronic acid in pediatric patients with bone malignancies. BONE, 68. pp. 146-152. ISSN 8756-3282
Lamora, A., Talbot, J., Bougras, G. et al. (10 more authors) (2014) Overexpression of Smad7 Blocks Primary Tumor Growth and Lung Metastasis Development in Osteosarcoma. Clinical Cancer Research, 20 (19). pp. 5097-5112. ISSN 1078-0432
Lamoureux, F., Baud'huin, M., Ory, B. et al. (5 more authors) (2014) Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma. Oncotarget, 5 (17). pp. 7805-7819. ISSN 1949-2553
Gobin, B., Battaglia, S., Lanel, R. et al. (5 more authors) (2014) NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate. Cancer Letters, 344 (2). pp. 291-298. ISSN 0304-3835
Odri, G., Kim, P-P., Lamoureux, F. et al. (6 more authors) (2014) Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration. BMC Cancer, 14. 169. ISSN 1471-2407
Gobin, B., Moriceau, G., Ory, B. et al. (5 more authors) (2014) Imatinib Mesylate Exerts Anti-Proliferative Effects on Osteosarcoma Cells and Inhibits the Tumour Growth in Immunocompetent Murine Models. PLoS ONE, 9 (3). e90795. ISSN 1932-6203
Lamoureux, F., Baud'huin, M., Calleja, L.R. et al. (7 more authors) (2014) Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle. NATURE COMMUNICATIONS, 5. ARTN 3511. ISSN 2041-1723
Monderer, D., Luseau, A., Bellec, A. et al. (14 more authors) (2013) New chondrosarcoma cell lines and mouse models to study the link between chondrogenesis and chemoresistance. Laboratory Investigation, 93 (10). pp. 1100-1114. ISSN 0023-6837
Baud'huin, M.E., Duplomb, L., Teletchea, S. et al. (6 more authors) (2013) Osteoprotegerin: multiple partners for multiple functions. Cytokine and Growth Factor Reviews, 24 (5). pp. 401-409. ISSN 1359-6101
Redini, F., Odri, G.A., Picarda, G. et al. (4 more authors) (2013) Drugs targeting the bone microenvironment: new therapeutic tools in Ewing's sarcoma? Expert Opinion on Emerging Drugs, 18 (3). pp. 339-352. ISSN 1472-8214
Picarda, G., Matous, E., Amiaud, J. et al. (8 more authors) (2013) Osteoprotegerin inhibits bone resorption and prevents tumor development in a xenogenic model of Ewing's sarcoma by inhibiting RANKL. Journal of Bone Oncology, 2 (3). pp. 95-104. ISSN 2212-1374
Georges, S., Chesneau, J., Hervouet, S. et al. (7 more authors) (2013) A Disintegrin And Metalloproteinase 12 produced by tumour cells accelerates osteosarcoma tumour progression and associated osteolysis. European Journal of Cancer, 49 (9). pp. 2253-2263. ISSN 0959-8049
Miot-Noirault, E., David, E., Vidal, A. et al. (8 more authors) (2013) Tc-99m-NTP 15-5 assessment of the early therapeutic response of chondrosarcoma to zoledronic acid in the Swarm rat orthotopic model. EJNMMI Research, 3. 40. ISSN 2191-219X
Talbot, J., Brion, R., Picarda, G. et al. (8 more authors) (2013) Loss of connexin43 expression in Ewing's sarcoma cells favors the development of the primary tumor and the associated bone osteolysis. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1832 (4). pp. 553-564. ISSN 0925-4439
David, E., Tirode, F., Baud'huin, M. et al. (7 more authors) (2012) Oncostatin M Is a Growth Factor for Ewing Sarcoma. The American Journal of Pathology, 181 (5). pp. 1782-1795. ISSN 0002-9440
Peyrode, C., Weber, V., David, E. et al. (10 more authors) (2012) Quaternary ammonium-melphalan conjugate for anticancer therapy of chondrosarcoma: in vitro and in vivo preclinical studies. Investigational New Drugs, 30 (4). pp. 1782-1790. ISSN 0167-6997
Guihard, P., Danger, Y., Brounais, B. et al. (9 more authors) (2012) Induction of Osteogenesis in Mesenchymal Stem Cells by Activated Monocytes/Macrophages Depends on Oncostatin M Signaling. Stem Cells, 30 (4). pp. 762-772. ISSN 1066-5099
Picarda, G., Surget, S., Guiho, R. et al. (7 more authors) (2012) A Functional, New Short Isoform of Death Receptor 4 in Ewing's Sarcoma Cell Lines May be Involved in TRAIL Sensitivity/Resistance Mechanisms. Molecular Cancer Research, 10 (3). pp. 336-346. ISSN 1541-7786
Moriceau, G., Roelofs, A.J., Brion, R. et al. (4 more authors) (2012) Synergistic inhibitory effect of apomine and lovastatin on osteosarcoma cell growth. Cancer, 118 (3). pp. 750-760. ISSN 0008-543X
Picarda, G., Trichet, V., Teletchea, S. et al. (2 more authors) (2012) TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment. American Journal of Cancer Research, 2 (1). pp. 45-64. ISSN 2156-6976
Rousseau, J., Escriou, V., Lamoureux, F. et al. (8 more authors) (2011) Formulated siRNAs Targeting Rankl Prevent Osteolysis and Enhance Chemotherapeutic Response in Osteosarcoma Models. Journal of Bone and Mineral Research, 26 (10). pp. 2452-2462. ISSN 0884-0431
Battaglia, S., Dumoucel, S., Chesneau, J. et al. (6 more authors) (2011) Impact of Oncopediatric Dosing Regimen of Zoledronic Acid on Bone Growth: Preclinical Studies and Case Report of an Osteosarcoma Pediatric Patient. Journal of Bone and Mineral Research, 26 (10). pp. 2439-2451. ISSN 0884-0431
David, E., Guihard, P., Brounais, B. et al. (10 more authors) (2011) Direct anti-cancer effect of oncostatin M on chondrosarcoma. International Journal of Cancer, 128 (8). pp. 1822-1835. ISSN 0020-7136
Ando, K., Mori, K., Corradini, N. et al. (2 more authors) (2011) Mifamurtide for the treatment of nonmetastatic osteosarcoma. Expert Opinion on Pharmacotherapy, 2 (12). pp. 285-292. ISSN 1465-6566
Baud'huin, M., Ruiz-Velasco, C., Jego, G. et al. (9 more authors) (2011) Glycosaminoglycans inhibit the adherence and the spreading of osteoclasts and their precursors: Role in osteoclastogenesis and bone resorption. European Journal of Cell Biology, 90 (1). pp. 49-57. ISSN 0171-9335
Baud'huin, M., Ruiz-Velasco, C., Jego, G. et al. (9 more authors) (2011) Glycosaminoglycans inhibit the adherence and the spreading of osteoclasts and their precursors: Role in osteoclastogenesis and bone resorption. European Journal of Cell Biology, 90 (1). pp. 49-57. ISSN 0171-9335
Peyrode, C., Gouin, F., Vidal, A. et al. (8 more authors) (2011) A“Proteoglycan Targeting Strategy” for the Scintigraphic Imaging and Monitoring of the Swarm Rat Chondrosarcoma Orthotopic Model. Sarcoma, 2011. 691608. ISSN 1357-714X
Moriceau, G., Ory, B., Mitrofan, L. et al. (11 more authors) (2010) Zoledronic Acid Potentiates mTOR Inhibition and Abolishes the Resistance of Osteosarcoma Cells to RAD001 (Everolimus): Pivotal Role of the Prenylation Process. Cancer Research, 70 (24). pp. 10329-10339. ISSN 0008-5472
Odri, G.A., Dumoucel, S., Picarda, G. et al. (10 more authors) (2010) Zoledronic Acid as a New Adjuvant Therapeutic Strategy for Ewing's Sarcoma Patients. Cancer Research, 70 (19). pp. 7610-7619. ISSN 0008-5472
Velasco, C.R., Colliec-Jouault, S., Redini, F. et al. (2 more authors) (2010) Proteoglycans on bone tumor development. Drug Discovery Today, 15 (13-14). pp. 553-560. ISSN 1359-6446
Perrot, P., Rousseau, J., Bouffaut, A-L. et al. (8 more authors) (2010) Safety Concern between Autologous Fat Graft, Mesenchymal Stem Cell and Osteosarcoma Recurrence. PLOS ONE, 5 (6). e10999. ISSN 1932-6203
Rousseau, J., Escriou, V., Perrot, P. et al. (6 more authors) (2010) Advantages of bioluminescence imaging to follow siRNA or chemotherapeutic treatments in osteosarcoma preclinical models. Cancer Gene Therapy , 17 (6). pp. 387-397. ISSN 0929-1903
Picarda, G., Lamoureux, F., Geffroy, L. et al. (7 more authors) (2010) Preclinical Evidence that Use of TRAIL in Ewing's Sarcoma and Osteosarcoma Therapy Inhibits Tumor Growth, Prevents Osteolysis, and Increases Animal Survival. Clinical Cancer Research, 16 (8). pp. 2363-2374. ISSN 1078-0432
Moriceau, G., Ory, B., Gobin, B. et al. (5 more authors) (2010) Therapeutic Approach of Primary Bone Tumours by Bisphosphonates. Current Pharmaceutical Design, 16 (27). pp. 2981-2987. ISSN 1381-6128
Le Goff, B., Soltner, E., Charrier, C. et al. (4 more authors) (2009) A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis. Arthritis Research & Therapy, 11 (6). R185. ISSN 1478-6354
Brounais, B., David, E., Chipoy, C. et al. (8 more authors) (2009) Long term oncostatin M treatment induces an osteocyte-like differentiation on osteosarcoma and calvaria cells. Bone, 44 (5). pp. 830-839. ISSN 8756-3282
Mori, K., Ando, K., Heymann, D. orcid.org/0000-0001-7777-0669 et al. (1 more author) (2009) Receptor activator of nuclear factor-kappa B ligand (RANKL) stimulates bone-associated tumors through functional RANK expressed on bone-associated cancer cells? Histology and Histopathology, 24 (2). pp. 235-242. ISSN 0213-3911
Lamoureux, F., Picarda, G., Garrigue-Antar, L. et al. (7 more authors) (2009) Glycosaminoglycans as Potential Regulators of Osteoprotegerin Therapeutic Activity in Osteosarcoma. Cancer Research, 69 (2). pp. 526-536. ISSN 0008-5472
Chauvin, C., Philippeau, J-M., Hemont, C. et al. (7 more authors) (2008) Killer Dendritic Cells Link Innate and Adaptive Immunity against Established Osteosarcoma in Rats. Cancer Research, 68 (22). pp. 9433-9440. ISSN 0008-5472
Mori, K., Blanchard, F., Charrier, C. et al. (6 more authors) (2008) Conditioned media from mouse osteosarcoma cells promote MC3T3-E1 cell proliferation using JAKs and PI3-K/Akt signal crosstalk. Cancer Science, 99 (11). pp. 2170-2176. ISSN 1347-9032
Brounais, B., Ruiz, C., Rousseau, J. et al. (4 more authors) (2008) Novel Anti-Cancer Strategy in Bone Tumors by Targeting Molecular and Cellular Modulators of Bone Resorption. Recent Patents on Anti-Cancer Drug Discovery, 3 (3). pp. 178-186. ISSN 1574-8928
Lamoureux, F., Picarda, G., Rousseau, J. et al. (6 more authors) (2008) Therapeutic efficacy of soluble receptor activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma. Molecular Cancer Therapeutics, 7 (10). pp. 3389-3398. ISSN 1535-7163
Brounais, B., Chipoy, C., Mori, K. et al. (7 more authors) (2008) Oncostatin M induces bone loss and sensitizes rat osteosarcoma to the antitumor effect of midostaurin in vivo. Clinical Cancer Research, 14 (17). pp. 5400-5409. ISSN 1078-0432
Lamoureux, F., Ory, B., Battaglia, S. et al. (6 more authors) (2008) Relevance of a new rat model of osteoblastic metastases from prostate carcinoma for preclinical studies using zoledronic acid. International Journal of Cancer, 122 (4). pp. 751-760. ISSN 0020-7136
Mori, K., Berreur, M., Blanchard, F. et al. (5 more authors) (2007) Receptor activator of nuclear factor-kappa B ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells. Oncology Reports, 18 (6). pp. 1365-1371. ISSN 1021-335X
Chipoy, C., Brounais, B., Trichet, V. et al. (7 more authors) (2007) Sensitization of osteosarcoma cells to apoptosis by oncostatin M depends on STAT5 and p53. Oncogene, 26 (46). pp. 6653-6664. ISSN 0950-9232
Baud'huin, M., Lamoureuxa, F., Duplomba, L. et al. (2 more authors) (2007) RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases. Cellular and Molecular Life Sciences, 64 (18). pp. 2334-2350. ISSN 1420-682X
Lamoureux, F., Richard, P., Wittrant, Y. et al. (8 more authors) (2007) Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: Blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Research, 67 (15). pp. 7308-7318. ISSN 0008-5472
Perrot, P., Heymann, D. orcid.org/0000-0001-7777-0669, Charrier, C. et al. (3 more authors) (2007) Extraosseous bone formation obtained by association of mesenchymal stem cells with a periosteal flap in the rat. Annals of Plastic Surgery, 59 (2). pp. 201-206. ISSN 0148-7043
Lamoureux, F., Baud'huin, M., Duplomb, L. et al. (2 more authors) (2007) Proteoglycans: key partners in bone cell biology. BioEssays, 29 (8). pp. 758-771. ISSN 0265-9247
Mori, K., Le Goff, B., Charrier, C. et al. (3 more authors) (2007) DU145 human prostate cancer cells express functional receptor activator of NF kappa B: New insights in the prostate cancer bone metastasis process. Bone , 40 (4). pp. 981-990. ISSN 8756-3282
Mori, K., Le Goff, B., Berreur, M. et al. (11 more authors) (2007) Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B. The Journal of Pathology, 211 (5). pp. 555-562. ISSN 0022-3417
Ory, B., Blanchard, F., Battaglia, S. et al. (3 more authors) (2007) Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status. Molecular Pharmacology, 71 (1). pp. 333-343. ISSN 0026-895X
Ory, B., Moriceau, G., Redini, F. et al. (1 more author) (2007) mTOR inhibitors (rapamycin and its derivatives) and nitrogen containing bisphosphonates: Bi-functional compounds for the treatment of bone tumours. Current Medicinal Chemistry, 14 (13). pp. 1381-1387. ISSN 0929-8673
Tat, S.K., Padrines, M., Theoleyre, S. et al. (4 more authors) (2006) OPG/membranous-RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation. Bone, 39 (4). pp. 706-715. ISSN 8756-3282
Gouin, F., Ory, B., Redini, F. et al. (1 more author) (2006) Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival. International Journal of Cancer, 119 (5). pp. 980-984. ISSN 0020-7136
Theoleyre, S., Tat, S.K., Vusio, P. et al. (7 more authors) (2006) Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: Role in the interactions with receptor activator of nuclear factor kappa B ligand (RANKL) and RANK. Biochemical and Biophysical Research Communications, 347 (2). pp. 460-467. ISSN 0006-291X
Mori, K., Redini, F., Gouin, F. et al. (2 more authors) (2006) Osteosarcoma: Current status of immunotherapy and future trends (Review). Oncology Reports, 15 (3). pp. 693-700. ISSN 1021-335X
Wittrant, Y., Lamoureux, F., Mori, K. et al. (4 more authors) (2006) RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells. International Journal of Oncology, 28 (1). pp. 261-269. ISSN 1019-6439
Ory, B., Heymann, M.F., Kamijo, A. et al. (3 more authors) (2005) Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer, 104 (11). pp. 2522-2529. ISSN 0008-543X
Theoleyre, S., Mori, K., Cherrier, B. et al. (4 more authors) (2005) Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma. BMC Cancer, 5. 123. ISSN 1471-2407
Heymann, D. orcid.org/0000-0001-7777-0669, Ory, B., Blanchard, F. et al. (7 more authors) (2005) Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone , 37 (1). pp. 74-86. ISSN 8756-3282
Heymann, D. orcid.org/0000-0001-7777-0669, Fortun, Y., Redini, F. et al. (1 more author) (2005) Osteolytic bone diseases: physiological analogues of bone resorption effectors as alternative therapeutic tools. Drug Discovery Today, 10 (4). pp. 242-247. ISSN 1359-6446
Cherrier, B., Gouin, F., Heymann, M.F. et al. (4 more authors) (2005) A new experimental rat model of osteosarcoma established by intrafemoral tumor cell inoculation, useful for biology and therapy investigations. Tumor Biology, 26 (3). pp. 121-130. ISSN 1010-4283
Theoleyre, S., Wittrant, Y., Tat, S.K. et al. (3 more authors) (2004) The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine & Growth Factor Reviews, 15 (6). pp. 457-475. ISSN 1359-6101
Chipoy, C., Berreur, M., Couillaud, S. et al. (6 more authors) (2004) Downregulation of osteoblast markers and induction of the glial fibrillary acidic protein by oncostatin m in osteosarcoma cells require PKC delta and STAT3. Journal of Bone and Mineral Research (JBMR), 19 (11). pp. 1850-1861. ISSN 0884-0431
Wittrant, Y., Theoleyre, S., Chipoy, C. et al. (4 more authors) (2004) RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1704 (2). pp. 49-57. ISSN 0304-419X
Heymann, D. orcid.org/0000-0001-7777-0669, Ory, B., Gouin, F. et al. (2 more authors) (2004) Bisphosphonates: new therapeutic agents for the treatment of bone tumors. Trends in Molecular Medicine, 10 (7). pp. 337-343. ISSN 1471-4914
Wittrant, Y., Theoleyre, S., Couillaud, S. et al. (3 more authors) (2004) Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kappa B ligand and osteoprotegerin biological activities. Experimental Cell Research, 293 (2). pp. 292-301. ISSN 0014-4827
Grimaud, E., Soubigou, L., Couillaud, S. et al. (6 more authors) (2003) Receptor activator of nuclear factor kappa B ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. The American Journal of Pathology, 163 (5). pp. 2021-2031. ISSN 0002-9440
Wittrant, Y., Theoleyre, S., Couillaud, S. et al. (3 more authors) (2003) Regulation of osteoclast protease expression by RANKL. Biochemical and Biophysical Research Communications, 310 (3). pp. 774-778. ISSN 0006-291X
Wittrant, Y., Couillaud, S., Theoleyre, S. et al. (3 more authors) (2002) Osteoprotegerin differentially regulates protease expression in osteoclast cultures. Biochemical and Biophysical Research Communications, 293 (1). pp. 38-44. ISSN 0006-291X